TICKERNERD
Menu
VCYTVCYTHealthcare · Diagnostics & Research

VCYT Stock Forecast: Veracyte, Inc. Price Predictions for 2026-2027

Last close, 18 Sept 2026
$40
−1.91% on the day

The 13 Wall Street analysts covering Veracyte, Inc. hold a median 12-month price target of $59 — +48.3% from the last close. Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 95 of 100 as at 19 Sept 2026 — among the strongest tenth. Here, the model and the Street point the same way.

Market cap
$3.2B
Ticker Nerd rank
95 / 100
Median analyst target
$59
Analysts covering
13
Revenue$150.3M+15.5% y/y
Operating income$23.0M
Net income$25.5M
Free cash flow$43.0M
Quarterly, 8 quarters to 30 June 2026 · latest quarter's figure shown
Total return, dividends reinvested
1W
−2.6%
1M
−2.2%
YTD
−5.5%
1Y
+19.8%
From 52W high
−34.2%
From 52W low
+32.6%
$30
$60
52-week range, adjusted closes · the dot is the last close
Ticker Nerd rank

VCYT stock analysis: one number for the whole business

Consensus tells you what everyone already believes. The model scores Veracyte, Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.

Where the model ranks itAs at 19 Sept 2026
95 / 100

Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested

Value
92
Quality
90
Growth
83
Revisions
80
Volatility
68
Issuance
64
Momentum
64
Accruals
64
Size
29

Value (92): The shares cost little relative to the profits and assets behind them — which can mean the market is too gloomy, or that the business really is in trouble.

Accruals (64): A large share of reported profit has not shown up as cash, or the balance sheet is expanding quickly — both tend to unwind.

Size (29): Larger than most of the companies we track — more scrutinised, less often mispriced.

Built and run by Aslam Ghouse, an ex-Goldman Sachs quant trader with fourteen years in markets.

Wall Street

VCYT stock forecast 2026-2027: analyst price targets & predictions

The bullish and bearish analyst opinions on VCYT, reported as data — targets and ratings, the market's view beside the model's.

Share price and the analyst range, 12 monthsAdjusted close, US dollars
$30$40$50$60$70Oct 25Jan 26Apr 26Jul 26VCYTHigh $70Median $59Low $44

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Data provided by Twelve Data

What Wall Street says13 analysts
11 Buy1 Hold1 Sell
Low $44Median $59High $70

The green dot is the last close — the median target sits +48.3% from it.

Recent analyst actionsNewest first

Of the 20 most recent actions, 5 moved their price target up and 4 moved it down.

DateFirmActionRatingTarget
15 Sept 2026Freedom Capital MarketsMaintainsBuy$66
9 Sept 2026UBSMaintainsBuy$52 → $65
4 Aug 2026Morgan StanleyMaintainsUnderweight—
4 Aug 2026Morgan StanleyMaintainsUnderweight$47 → $44
4 Aug 2026Piper SandlerMaintainsOverweight$66 → $54
4 Aug 2026Piper SandlerMaintainsOverweight—
4 Aug 2026Stephens & Co.MaintainsOverweight$68 → $55
4 Aug 2026Stephens & Co.MaintainsOverweight—
3 Aug 2026Canaccord GenuityMaintainsHold—
3 Aug 2026Canaccord GenuityMaintainsHold$60 → $50
31 July 2026NeedhamMaintainsBuy—
31 July 2026NeedhamMaintainsBuy$57 → $69
30 July 2026NeedhamMaintainsBuy$57 → $69
30 July 2026NeedhamMaintainsBuy—
15 July 2026Piper SandlerInitiatesOverweight$66
15 July 2026Piper SandlerInitiatesOverweight—
14 July 2026Canaccord GenuityMaintainsHold$42 → $60
14 July 2026Canaccord GenuityMaintainsHold—
9 July 2026Morgan StanleyMaintainsUnderweight$37 → $47
9 July 2026Morgan StanleyMaintainsUnderweight—

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Market Radar

This page is one stock. Monday covers all of them.

Computed off the Friday close and sent before the US open.

Market Radar reports the week’s largest rank changes across roughly 4,600 US stocks, the factor behind each one, and where the market went. VCYT appears on the weeks it earns a place.

Free, every Monday. Unsubscribe any time.

Performance

VCYT vs the S&P 500

Both lines are total return — dividends reinvested — so the comparison is honest on both sides.

Over the twelve months to 18 Sept 2026, Veracyte, Inc. returned +19.8% against +16.3% for the S&P 500, dividends included.

VCYT vs S&P 500, last 12 monthsTotal return, rebased to 100
80100120140160180Oct 25Jan 26Apr 26Jul 26VCYTS&P 500

Download this chart as an image — free to reuse; link this page as the source.

Data provided by Twelve Data

Estimates

VCYT analyst estimate revisions

Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.

Which way the estimates are movingNext fiscal year
EPS revision, 90 days
+4.9%
Analysts raising
10
Analysts cutting
0
Fundamentals

Veracyte, Inc. (VCYT) financial data

A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.

Valuation
Trailing P/E
28.4×

Cheaper than 27% of US stocks

Price / sales
5.7×

Cheaper than 22% of US stocks

Price / book
2.3×

Cheaper than 41% of US stocks

EV / EBITDA
24.3×

Cheaper than 11% of US stocks

Growth & margins
Revenue growth (YoY)
15.5%

Higher than 63% of US stocks

Earnings growth (YoY)
15.5%

Higher than 53% of US stocks

Gross margin
72.2%

Higher than 85% of US stocks

Operating margin
15.3%

Higher than 73% of US stocks

Net margin
20.4%

Higher than 82% of US stocks

Returns & dividend
Return on equity
8.8%

Higher than 60% of US stocks

Return on assets
4.1%

Higher than 71% of US stocks

Dividend yield
—

Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.

Key statistics

Veracyte, Inc. (VCYT) statistics: revenue, profit & scale

The headline figures, each with its date. Every row carries its own link — cite it straight from here.

  • Veracyte, Inc. has a market value of $3.2B and an enterprise value of $2.8B.

  • Revenue in the twelve months to 30 June 2026: $561.9M. The latest quarter grew 15.5% year on year.

  • Net income over the same four quarters: $114.5M, a 20.4% net margin.

  • Diluted earnings per share, trailing twelve months: $1.41.

  • Free cash flow in the twelve months to 30 June 2026: $166.0M.

  • Shares outstanding: 80.4M.

  • Trailing P/E: 28.4×; forward P/E: 20.4× — the forward figure prices analyst consensus estimates, not reported earnings.

  • Veracyte, Inc. employs 755 people — $744K of revenue per employee.

Statement figures: company filings via Twelve Data, four quarters to 30 June 2026 · market figures as at 19 Sept 2026

Data provided by Twelve Data

Peers

VCYT vs competitors

The nearest names by industry and size, scored by the same model — like for like.

Its peer group, ranked by the same modelDiagnostics & Research
CompanyMarket capTKN rank
VCYTVeracyte, Inc.$3.2B
95
WGSGeneDx Holdings Corp.$2.9B
44
GRALGRAIL, Inc.$3.6B
36
CDNACareDx, Inc.$2.8B
100
NEONeoGenomics, Inc.$2.6B
77
ADPTAdaptive Biotechnologies Corp.$4.6B
78
BLLNBillionToOne, Inc.$5.0B
15

Look up any of the roughly 4,600 stocks we score.

The rank is the raw material. Whether the rules would actually own Veracyte, Inc. — and when they’d sell — is the membership. See the Ticker Nerd 20 →

News

Latest VCYT news & analysis

Veracyte, Inc. (VCYT) Presents at Morgan Stanley 24th Annual Global Healthcare Conference Transcript

Seeking Alpha · 15 Sept 2026neutral

Veracyte, Inc. (VCYT) presented at the Morgan Stanley 24th Annual Global Healthcare Conference, and a transcript of its presentation was published by Seeking Alpha. The item reports on the company's participation in this investor conference.

Why it matters — A VCYT watcher would care because the conference presentation gives investors insight into management's public statements and the company's positioning at a major healthcare industry event.

Veracyte Acquires Convergent Genomics, Expanding its Urology Diagnostics Portfolio with a Urinary Tumor DNA Testing Platform

GlobeNewsWire · 14 Sept 2026positive

Veracyte has acquired Convergent Genomics, expanding its urology diagnostics portfolio with a urinary tumor DNA testing platform. The acquisition is positioned to enable Veracyte to deliver genomic insights from urine, tissue, and blood to guide bladder cancer care across the patient journey.

Why it matters — The acquisition adds a urinary tumor DNA testing platform to Veracyte's diagnostics portfolio, broadening its capabilities in bladder cancer care across urine, tissue, and blood.

3 Medical Instruments Stocks Banking on GenAI to Tackle Industry Woes

Zacks Investment Research · 9 Sept 2026neutral

Zacks Investment Research highlights GenAI as offering growth potential for medical instruments companies including Veracyte (VCYT), GMED, and UFPT. The report notes that regulatory and technology risks are likely to challenge the adoption of GenAI across healthcare.

Why it matters — This report places VCYT among a set of medical-instrument companies that could benefit from GenAI growth opportunities while facing adoption risks tied to regulation and technology.

Veracyte to Participate in the Morgan Stanley 24th Annual Global Healthcare Conference

GlobeNewsWire · 1 Sept 2026neutral

Veracyte, Inc. announced it will participate in a fireside chat at the Morgan Stanley 24th Annual Global Healthcare Conference on Tuesday, September 15, 2026, at 7:00 a.m. Eastern Time.

Why it matters — The company's participation in a major investor conference provides a public platform for management to discuss its business with the investment community.

Is it Worth Adding Veracyte Stock to Your Portfolio Now?

Zacks Investment Research · 26 Aug 2026neutral

Zacks Investment Research published an analysis assessing whether Veracyte stock is worth adding to portfolios. The piece notes that sales momentum in Veracyte's Afirma and Decipher products supports growth, while citing competition, macroeconomic pressures, and rising investments as key concerns.

Why it matters — VCYT watchers would care because the analysis weighs the company's growth drivers (Afirma and Decipher momentum) against the competitive and macro headwinds it faces.

FAQ

Frequently asked questions about VCYT stock

What is the VCYT stock price forecast for 2026-2027?

The 13 Wall Street analysts covering Veracyte, Inc. have a median 12-month price target of $59, with estimates ranging from $44 to $70. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.

Is VCYT stock a buy right now?

Of the 13 analysts covering Veracyte, Inc., 11 rate it a Buy, 1 a Hold and 1 a Sell. Ticker Nerd's systematic factor model ranks Veracyte, Inc. 95 out of 100 across roughly 4,600 US stocks as at 19 Sept 2026. None of this is personal advice — it does not consider your circumstances.

How does Ticker Nerd's model rank VCYT?

As at 19 Sept 2026, Veracyte, Inc. ranks 95 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Value (92 of 100).

Will VCYT stock go up?

No one can know that. What the data says: the median 12-month target from 13 analysts implies +48.3% from the last close, and Ticker Nerd's factor model ranks Veracyte, Inc. 95 out of 100 as at 19 Sept 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.

What is the VCYT stock forecast for 2030?

No analyst covering Veracyte, Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for VCYT are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $44 to $70 over the next 12 months.

How has VCYT stock performed over the past year?

Veracyte, Inc. returned +19.8% over the 12 months to 18 Sept 2026, with dividends reinvested. Past performance does not indicate future returns.

What does Veracyte, Inc. do?

Veracyte, Inc. is a precision diagnostics company that develops genomic tests to help clinicians answer critical questions in cancer and other diseases.

What is the latest news on VCYT?

The most recent item we track (Seeking Alpha, 15 Sept 2026): "Veracyte, Inc. (VCYT) Presents at Morgan Stanley 24th Annual Global Healthcare Conference Transcript". Veracyte, Inc. (VCYT) presented at the Morgan Stanley 24th Annual Global Healthcare Conference, and a transcript of its presentation was published by Seeking Alpha. The item reports on the company's participation in this investor conference.

Company

About Veracyte, Inc.

Veracyte, Inc. is a precision diagnostics company that develops genomic tests to help clinicians answer critical questions in cancer and other diseases. Veracyte’s current portfolio includes laboratory-developed tests for thyroid, prostate, bladder, and breast cancer, as well as tests for lung disease and lung cancer-related decision support. The company also provides products and services such as Afirma, Decipher, Percepta, Envisia, Prosigna, Immunoscore, and nCounter analysis capabilities, supporting diagnosis, prognosis, and treatment selection across multiple care settings. Its work is centered on using genomic and clinical data to reduce diagnostic uncertainty and improve decision-making for physicians, pathologists, and patients. Headquartered in South San Francisco, California, Veracyte operates as a global diagnostics business with a focus on molecular testing, evidence generation, and clinical utility in oncology and related specialties.

CEO Mr. Marc A. Stapley · 755 employees · United States · https://www.veracyte.com